MAT prescriptions may be associated with a mild increased risk of posterior NIU in the real-world setting, but not the low inflammatory risk setting, compared with SSRIs. These findings suggest a potential benefit of ophthalmologic monitoring in patients prescribed MAT, although institutional studies reviewing each medication are necessary to confirm these results.
Schulgit et al. (Tue,) studied this question.